Selexis SA and OSE Immunotherapeutics SA have signed a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform. The agreement builds upon previous collaboration between the two companies in November 2016 and is designed to support the advancement of the clinical development of OSE’s interleukin receptor 7 antagonist, OSE-127 (Effi-7), under development as a potential treatment for inflam...